Relay Therapeutics, Inc. Deferred Tax Assets, Operating Loss Carryforwards, Domestic
Relay Therapeutics, Inc. (RLAY) had Deferred Tax Assets, Operating Loss Carryforwards, Domestic of $923.90 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Operating Loss Carryforwards, Components
us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic · last filed 2026-02-26
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $923.90M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $596.30M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $498.00M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $412.10M; Deferred Tax Assets, Operating Loss Carryforwards, Domestic as first filed $412.00M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards, Domestic | Deferred Tax Assets, Operating Loss Carryforwards, Domestic as first filed |
|---|---|---|
| 2025-12-31 | $923.90M 10-K · filed 2026-02-26 | |
| 2024-12-31 | $596.30M 10-K · filed 2026-02-26 | |
| 2023-12-31 | $498.00M 10-K · filed 2025-02-26 | |
| 2022-12-31 | $412.10M 10-K · filed 2024-02-22 | $412.00M 10-K · filed 2023-02-23 |
| 2021-12-31 | $371.40M 10-K · filed 2023-02-23 | |
| 2020-12-31 | $174.00M 10-K · filed 2022-02-24 | $174.03M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |